StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The stock's significant drop reflects market disappointment over delayed trials. Historical precedents indicate that trial pauses often result in negative sentiment and price declines.
What happened, with direct paths to the underlying reporting
PepGen temporarily pauses Phase 2 study to evaluate previous cohort results. Data from the 10 mg/kg cohort expected in Q3 2025. No new safety issues reported since January 2025 update. Focus shifts towards completing CONNECT1 and advancing FREEDOM studies. PEPG stock down 21% at $2.22 following announcement.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.